Literature DB >> 24247928

AAV-mediated liver-specific MPV17 expression restores mtDNA levels and prevents diet-induced liver failure.

Emanuela Bottani1, Carla Giordano2, Gabriele Civiletto1, Ivano Di Meo1, Alberto Auricchio3, Emilio Ciusani4, Silvia Marchet1, Costanza Lamperti1, Giulia d'Amati2, Carlo Viscomi1, Massimo Zeviani5.   

Abstract

Mutations in human MPV17 cause a hepatocerebral form of mitochondrial DNA depletion syndrome (MDS) hallmarked by early-onset liver failure, leading to premature death. Liver transplantation and frequent feeding using slow-release carbohydrates are the only available therapies, although surviving patients eventually develop slowly progressive peripheral and central neuropathy. The physiological role of Mpv17, including its functional link to mitochondrial DNA (mtDNA) maintenance, is still unclear. We show here that Mpv17 is part of a high molecular weight complex of unknown composition, which is essential for mtDNA maintenance in critical tissues, i.e. liver, of a Mpv17 knockout mouse model. On a standard diet, Mpv17-/- mouse shows hardly any symptom of liver dysfunction, but a ketogenic diet (KD) leads these animals to liver cirrhosis and failure. However, when expression of human MPV17 is carried out by adeno-associated virus (AAV)-mediated gene replacement, the Mpv17 knockout mice are able to reconstitute the Mpv17-containing supramolecular complex, restore liver mtDNA copy number and oxidative phosphorylation (OXPHOS) proficiency, and prevent liver failure induced by the KD. These results open new therapeutic perspectives for the treatment of MPV17-related liver-specific MDS.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24247928      PMCID: PMC3880585          DOI: 10.1038/mt.2013.230

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  40 in total

1.  Isolation of biogenetically competent mitochondria from mammalian tissues and cultured cells.

Authors:  Erika Fernández-Vizarra; Manuel J López-Pérez; José A Enriquez
Journal:  Methods       Date:  2002-04       Impact factor: 3.608

2.  SIFT: Predicting amino acid changes that affect protein function.

Authors:  Pauline C Ng; Steven Henikoff
Journal:  Nucleic Acids Res       Date:  2003-07-01       Impact factor: 16.971

3.  Early growth response (EGR)-1 is required for timely cell-cycle entry and progression in hepatocytes after acute carbon tetrachloride exposure in mice.

Authors:  Michele T Pritchard; Robert N Malinak; Laura E Nagy
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-03-17       Impact factor: 4.052

4.  mTERF2 regulates oxidative phosphorylation by modulating mtDNA transcription.

Authors:  Tina Wenz; Corneliu Luca; Alessandra Torraco; Carlos T Moraes
Journal:  Cell Metab       Date:  2009-06       Impact factor: 27.287

5.  Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion.

Authors:  Alice Bourdon; Limor Minai; Valérie Serre; Jean-Philippe Jais; Emmanuelle Sarzi; Sophie Aubert; Dominique Chrétien; Pascale de Lonlay; Véronique Paquis-Flucklinger; Hirofumi Arakawa; Yusuke Nakamura; Arnold Munnich; Agnès Rötig
Journal:  Nat Genet       Date:  2007-05-07       Impact factor: 38.330

6.  Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder.

Authors:  I Nishino; A Spinazzola; M Hirano
Journal:  Science       Date:  1999-01-29       Impact factor: 47.728

7.  Sym1, the yeast ortholog of the MPV17 human disease protein, is a stress-induced bioenergetic and morphogenetic mitochondrial modulator.

Authors:  Cristina Dallabona; René Massimiliano Marsano; Paola Arzuffi; Daniele Ghezzi; Patrizia Mancini; Massimo Zeviani; Iliana Ferrero; Claudia Donnini
Journal:  Hum Mol Genet       Date:  2009-12-30       Impact factor: 6.150

8.  Infantile hepatocerebral syndromes associated with mutations in the mitochondrial DNA polymerase-gammaA.

Authors:  Gianfrancesco Ferrari; Eleonora Lamantea; Alice Donati; Massimiliano Filosto; Egill Briem; Franco Carrara; Rossella Parini; Alessandro Simonati; René Santer; Massimo Zeviani
Journal:  Brain       Date:  2005-02-02       Impact factor: 13.501

9.  Hepatocerebral form of mitochondrial DNA depletion syndrome due to mutation in MPV17 gene.

Authors:  Abdulaziz AlSaman; Hoda Tomoum; Federica Invernizzi; Massimo Zeviani
Journal:  Saudi J Gastroenterol       Date:  2012 Jul-Aug       Impact factor: 2.485

10.  Effective AAV-mediated gene therapy in a mouse model of ethylmalonic encephalopathy.

Authors:  Ivano Di Meo; Alberto Auricchio; Costanza Lamperti; Alberto Burlina; Carlo Viscomi; Massimo Zeviani
Journal:  EMBO Mol Med       Date:  2012-08-20       Impact factor: 12.137

View more
  21 in total

Review 1.  Mitochondrial Diseases Part III: Therapeutic interventions in mouse models of OXPHOS deficiencies.

Authors:  Susana Peralta; Alessandra Torraco; Luisa Iommarini; Francisca Diaz
Journal:  Mitochondrion       Date:  2015-01-29       Impact factor: 4.160

Review 2.  Therapeutic Approaches to Treat Mitochondrial Diseases: "One-Size-Fits-All" and "Precision Medicine" Strategies.

Authors:  Emanuela Bottani; Costanza Lamperti; Alessandro Prigione; Valeria Tiranti; Nicola Persico; Dario Brunetti
Journal:  Pharmaceutics       Date:  2020-11-11       Impact factor: 6.321

3.  The Human Mitochondrial DNA Depletion Syndrome Gene MPV17 Encodes a Non-selective Channel That Modulates Membrane Potential.

Authors:  Vasily D Antonenkov; Antti Isomursu; Daniela Mennerich; Miia H Vapola; Hans Weiher; Thomas Kietzmann; J Kalervo Hiltunen
Journal:  J Biol Chem       Date:  2015-04-10       Impact factor: 5.157

Review 4.  Emerging therapies for mitochondrial diseases.

Authors:  Michio Hirano; Valentina Emmanuele; Catarina M Quinzii
Journal:  Essays Biochem       Date:  2018-07-20       Impact factor: 8.000

Review 5.  Mitochondrial Membranes and Mitochondrial Genome: Interactions and Clinical Syndromes.

Authors:  Mohammed Almannai; Azza Salah; Ayman W El-Hattab
Journal:  Membranes (Basel)       Date:  2022-06-15

Review 6.  Gene therapy for primary mitochondrial diseases: experimental advances and clinical challenges.

Authors:  Micol Falabella; Michal Minczuk; Michael G Hanna; Carlo Viscomi; Robert D S Pitceathly
Journal:  Nat Rev Neurol       Date:  2022-10-18       Impact factor: 44.711

Review 7.  Mitochondrial Diseases Part II: Mouse models of OXPHOS deficiencies caused by defects in regulatory factors and other components required for mitochondrial function.

Authors:  Luisa Iommarini; Susana Peralta; Alessandra Torraco; Francisca Diaz
Journal:  Mitochondrion       Date:  2015-01-29       Impact factor: 4.160

8.  Canine MPV17 truncation without clinical manifestations.

Authors:  Reetta L Hänninen; Saija Ahonen; Merce Màrquez; Maarit J Myöhänen; Marjo K Hytönen; Hannes Lohi
Journal:  Biol Open       Date:  2015-09-09       Impact factor: 2.422

Review 9.  Mitochondrial diseases: advances and issues.

Authors:  Mauro Scarpelli; Alice Todeschini; Irene Volonghi; Alessandro Padovani; Massimiliano Filosto
Journal:  Appl Clin Genet       Date:  2017-02-15

Review 10.  Emerging therapies for mitochondrial disorders.

Authors:  Helen Nightingale; Gerald Pfeffer; David Bargiela; Rita Horvath; Patrick F Chinnery
Journal:  Brain       Date:  2016-05-03       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.